Skip to main content

Table 3 Overview of patient quality of life (QoL)

From: Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer

 

Pre-Treatment

1 Month

3 Month

6 Month

9 Month

12 Month

SF-12 PCS

50 (35.2 - 58.9)

50.9 (31.4 - 61.4)

50.5 (31.4 - 61.2)

50.6 (25.7 - 56.7)

49 (27.1 - 57.2)

49 (27.6 - 59.8)

SF-12 MCS

54.8 (37.2 - 61.3)

54.4 (41.2 - 61)

55.2 (37.3 - 63.2)

55.7 (34.5 - 61.5)

57 (47.1 - 64.7)

56.5 (38.5 - 62.6)

AUA

6.8 (1 - 21)

10.8 (3 - 20)

8.1 (1 - 21)

7.7 (1 - 23)

7.5 (2 - 26)

7.4 (0 - 22)

SHIM

17.2 (3 - 25)

16 (1 - 25)

15 (1 - 25)

15.2 (1 - 25)

15.6 (1 - 25)

14.3 (1 - 25)

EPIC Urinary

90.5 (63 - 100)

82.7 (61.1 - 100)

87.7 (53.7 - 100)

88.5 (65.8 - 100)

88.1 (68.6 - 100)

89 (60.2 - 100)

EPIC Bowel

95.7 (66.7 - 100)

91.7 (62.5 - 100)

92.6 (66.7 - 100)

94.1 (70.8 - 100)

94.1 (62.5 - 100)

94.8 (75 - 100)

EPIC Sexual

66.7 (27.8 - 95.8)

66.4 (20.8 - 100)

59.9 (0 - 100)

59.8 (0 - 100)

60 (16.7 - 100)

60.1 (13.8 - 100)

EPIC Hormonal

94.2 (75 - 100)

90.9 (70 - 100)

90.8 (60 - 100)

92.3 (60 - 100)

93.6 (60 - 100)

92.1 (60 - 100)

  1. The table shows unadjusted changes in mean toxicity and QOL scores over time. SF-12 scores range from 0 - 100 with higher values representing improved health status. AUA scores range from 0 - 35 with higher values representing worsening urinary symptoms. SHIM scores range from 0 - 25 with lower values representing worsening sexual function. EPIC scores range from 0 - 100 with higher values representing a more favorable health-related QOL. Bolded items signify a statistically significant change in reported QoL from baseline measured by Wilcoxon rank sum test at 0.05 significance level.